Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Baker T, Sharifian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, White WI, Ferrari N, Muthas D, Tummala R, Morand EF, Furie R, Vital EM, Chamberlain C, Platt A, Al-Mossawi H, Brohawn PZ, Csomor E.
Baker T, et al. Among authors: ramaswamy m.
Ann Rheum Dis. 2024 May 3:ard-2023-225445. doi: 10.1136/ard-2023-225445. Online ahead of print.
Ann Rheum Dis. 2024.
PMID: 38569851
Free article.